[{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"641e6271-0e87-4441-87f5-e22bb1c67e28","acronym":"IFN\u0026SMP","url":"https://clinicaltrials.gov/study/NCT05850273","created_at":"2023-05-09T14:04:26.422Z","updated_at":"2025-02-25T16:54:57.682Z","phase":"","brief_title":"Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms","source_id_and_acronym":"NCT05850273 - IFN\u0026SMP","lead_sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","biomarkers":" CD38 • CD34 • THY1","pipe":"","alterations":" ","tags":["CD38 • CD34 • THY1"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 03/16/2028","primary_completion_date":" 03/16/2028","study_txt":" Completion: 03/16/2033","study_completion_date":" 03/16/2033","last_update_posted":"2025-02-04"},{"id":"da7c1c4e-12fb-4361-97e1-5845011e3482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243190","created_at":"2021-01-18T05:00:24.541Z","updated_at":"2025-02-25T13:16:23.958Z","phase":"Phase 2","brief_title":"Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT01243190","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH • CD38","pipe":" | ","alterations":" CD38 positive","tags":["IGH • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 03/28/2023","study_completion_date":" 03/28/2023","last_update_posted":"2024-09-19"},{"id":"03e89ab8-dacb-455b-84eb-7a4c304f5cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06338657","created_at":"2024-03-29T14:40:53.948Z","updated_at":"2024-07-02T16:35:02.933Z","phase":"Phase 1","brief_title":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","source_id_and_acronym":"NCT06338657","lead_sponsor":"University of Southern California","biomarkers":" PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nanoencapsulated paclitaxel (FID-007)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-17"},{"id":"75cf148e-b887-4424-83a5-20bddaa84fcb","acronym":"FRAIL-IMMUNE","url":"https://clinicaltrials.gov/study/NCT03723967","created_at":"2024-04-22T19:24:32.939Z","updated_at":"2024-07-02T16:35:08.471Z","phase":"Phase 2","brief_title":"FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel","source_id_and_acronym":"NCT03723967 - FRAIL-IMMUNE","lead_sponsor":"Centre Leon Berard","biomarkers":" CD20 • CD8 • CD38 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD20 • CD8 • CD38 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 05/16/2020","primary_completion_date":" 05/16/2020","study_txt":" Completion: 03/09/2024","study_completion_date":" 03/09/2024","last_update_posted":"2024-04-22"},{"id":"dc5b63d1-d71c-461a-9555-93d27bcb4d1c","acronym":"PRO00041908","url":"https://clinicaltrials.gov/study/NCT05038644","created_at":"2021-09-09T13:53:03.633Z","updated_at":"2024-07-02T16:35:11.572Z","phase":"Phase 1","brief_title":"XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia","source_id_and_acronym":"NCT05038644 - PRO00041908","lead_sponsor":"Ehab L Atallah","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XmAb968"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-03"},{"id":"6b3f889b-f740-4f3b-8cf4-23be6228dabd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684108","created_at":"2021-01-19T20:47:15.713Z","updated_at":"2024-07-02T16:35:12.449Z","phase":"Phase 1","brief_title":"SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies","source_id_and_acronym":"NCT04684108","lead_sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SG301 IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-28"},{"id":"b5852439-4741-4042-bbae-cd64f468c295","acronym":"","url":"https://clinicaltrials.gov/study/NCT01028430","created_at":"2021-01-18T04:02:12.824Z","updated_at":"2024-07-02T16:35:12.551Z","phase":"","brief_title":"B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging","source_id_and_acronym":"NCT01028430","lead_sponsor":"Northwell Health","biomarkers":" CD38","pipe":"","alterations":" ","tags":["CD38"],"overall_status":"Completed","enrollment":" Enrollment 1000","initiation":"Initiation: 07/01/1998","start_date":" 07/01/1998","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2024-03-27"},{"id":"bdb1c58a-74c6-4750-9dd9-d9830096d0d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291444","created_at":"2021-01-18T16:15:39.130Z","updated_at":"2024-07-02T16:35:14.542Z","phase":"Phase 1","brief_title":"CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS","source_id_and_acronym":"NCT03291444","lead_sponsor":"Zhujiang Hospital","biomarkers":" KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA","pipe":" | ","alterations":" CD20 positive","tags":["KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/05/2018","start_date":" 05/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"8a9ebf00-3ead-4be6-b6da-08e24836e50c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011422","created_at":"2021-08-18T14:53:38.899Z","updated_at":"2024-07-02T16:35:15.459Z","phase":"Phase 1","brief_title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","source_id_and_acronym":"NCT05011422","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10","pipe":" | ","alterations":" MLL rearrangement • NUP98 rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • NUP98 rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-03-11"},{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"29682c29-0f75-49fe-996f-9470896b7c6c","acronym":"RICEPS","url":"https://clinicaltrials.gov/study/NCT04804137","created_at":"2021-03-18T12:53:00.521Z","updated_at":"2024-07-02T16:35:23.163Z","phase":"","brief_title":"Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study","source_id_and_acronym":"NCT04804137 - RICEPS","lead_sponsor":"University Hospital, Tours","biomarkers":" EGFR • BRAF • ROS1 • CD8 • CD38","pipe":"","alterations":" ","tags":["EGFR • BRAF • ROS1 • CD8 • CD38"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 09/26/2022","primary_completion_date":" 09/26/2022","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2024-01-17"},{"id":"67a15808-0681-4add-b990-145069d8cdb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714372","created_at":"2021-01-19T20:53:07.373Z","updated_at":"2024-07-02T16:35:23.907Z","phase":"Phase 1","brief_title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","source_id_and_acronym":"NCT04714372","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • IDH1 • IDH2 • CD38","pipe":" | ","alterations":" CD38 expression","tags":["FLT3 • IDH1 • IDH2 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 01/09/2024","primary_completion_date":" 01/09/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2024-01-10"},{"id":"0f0997b4-e016-4774-9c8c-8817ae0fe8c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05462496","created_at":"2022-07-18T14:01:45.193Z","updated_at":"2024-07-02T16:35:28.767Z","phase":"Phase 2","brief_title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","source_id_and_acronym":"NCT05462496","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" CD38 • IL2RA • CD69 • ISG20","pipe":"","alterations":" ","tags":["CD38 • IL2RA • CD69 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-18"},{"id":"d13f56b0-8639-4208-b539-4823e51034c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06110208","created_at":"2023-10-31T18:13:47.101Z","updated_at":"2025-02-25T15:01:08.534Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML","source_id_and_acronym":"NCT06110208","lead_sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","biomarkers":" CD38","pipe":"","alterations":" ","tags":["CD38"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-31"},{"id":"50192133-c8e8-4b6f-9edf-895d64f162f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05995041","created_at":"2023-08-16T16:08:27.797Z","updated_at":"2024-07-02T16:35:33.734Z","phase":"Phase 1","brief_title":"Universal CAR-T Cells Targeting AML","source_id_and_acronym":"NCT05995041","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD38 • CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-12"},{"id":"3c4991de-db64-4065-98be-20d6b4e3f446","acronym":"","url":"https://clinicaltrials.gov/study/NCT03848676","created_at":"2021-01-18T18:59:48.511Z","updated_at":"2024-07-02T16:35:36.215Z","phase":"","brief_title":"Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma","source_id_and_acronym":"NCT03848676","lead_sponsor":"University of Turin, Italy","biomarkers":" CD8 • IL6 • CD38 • CRBN • DKK1 • CD4 • CD55 • CD59","pipe":" | ","alterations":" CD38 expression • CRBN mutation","tags":["CD8 • IL6 • CD38 • CRBN • DKK1 • CD4 • CD55 • CD59"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CRBN mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-09-21"},{"id":"8d47bbb6-06cc-480c-98ad-8a291714a09d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05442580","created_at":"2022-07-05T14:54:23.025Z","updated_at":"2024-07-02T16:35:45.090Z","phase":"Phase 1","brief_title":"CART-38 in Adult AML and MM Patients","source_id_and_acronym":"NCT05442580","lead_sponsor":"University of Pennsylvania","biomarkers":" CD38 • CD34","pipe":" | ","alterations":" CD38 expression","tags":["CD38 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CART-38"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/01/2041","primary_completion_date":" 05/01/2041","study_txt":" Completion: 05/01/2041","study_completion_date":" 05/01/2041","last_update_posted":"2023-06-22"},{"id":"1a20e268-2930-4294-b911-885f239ea93c","acronym":"DILEMMA","url":"https://clinicaltrials.gov/study/NCT05835726","created_at":"2023-04-28T15:04:55.549Z","updated_at":"2024-07-02T16:35:49.208Z","phase":"","brief_title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","source_id_and_acronym":"NCT05835726 - DILEMMA","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CD38 • CD34","pipe":" | ","alterations":" CD38 expression","tags":["CD38 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Darzalex (daratumumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-05-01"},{"id":"2add9cbf-45b6-4ca2-b88c-b9bfd4516d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007418","created_at":"2021-08-16T16:54:44.805Z","updated_at":"2024-07-02T16:35:57.559Z","phase":"Phase 1b","brief_title":"Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05007418","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STI-1492"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-01-16"},{"id":"b1d5a974-0b04-421b-8acb-a796d504456e","acronym":"IDA53","url":"https://clinicaltrials.gov/study/NCT03734198","created_at":"2021-01-18T18:17:21.383Z","updated_at":"2024-07-02T16:36:08.182Z","phase":"Phase 2","brief_title":"Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction","source_id_and_acronym":"NCT03734198 - IDA53","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" TP53 • CD38","pipe":" | ","alterations":" TP53 mutation • CD38 expression","tags":["TP53 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Darzalex (daratumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-06-28"},{"id":"f5ce5e9d-2a3d-4cf4-9915-fcca832b827b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05277753","created_at":"2022-03-14T14:54:15.233Z","updated_at":"2024-07-02T16:36:15.399Z","phase":"Phase 1","brief_title":"NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL","source_id_and_acronym":"NCT05277753","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD47 • CD5 • CD7","pipe":"","alterations":" ","tags":["CD38 • CD47 • CD5 • CD7"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-15"},{"id":"c54753d7-1cf4-46f7-9de1-57a9fb61c4cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00951457","created_at":"2021-01-18T03:42:02.659Z","updated_at":"2024-07-02T16:36:16.114Z","phase":"Phase 1/2","brief_title":"Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT00951457","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" CD38 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 08/06/2012","primary_completion_date":" 08/06/2012","study_txt":" Completion: 08/06/2012","study_completion_date":" 08/06/2012","last_update_posted":"2022-03-03"},{"id":"5fad71d4-a395-4a9d-9bc6-39b3d673e45a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01276236","created_at":"2021-01-29T07:01:30.935Z","updated_at":"2024-07-02T16:36:33.752Z","phase":"Phase 2","brief_title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","source_id_and_acronym":"NCT01276236","lead_sponsor":"University of California, San Francisco","biomarkers":" CD8 • CD38 • CD4 • CD69","pipe":" | ","alterations":" CD38 positive • CD8 negative","tags":["CD8 • CD38 • CD4 • CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive • CD8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/09/2011","start_date":" 03/09/2011","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 04/30/2015","study_completion_date":" 04/30/2015","last_update_posted":"2021-03-05"}]